Cloudbreak Pharmaceutical
Cloudbreak Pharma is a clinical-stage ophthalmic drug company developing treatments for eye diseases, including the first therapeutic for pterygia.
Secondary Market Price
How Cloudbreak Pharmaceutical Measures Up
To help you manage your Cloudbreak Pharmaceutical equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
TBD
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Cloudbreak Pharmaceutical's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Cloudbreak Pharmaceutical Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Cloudbreak Pharmaceutical's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Cloudbreak Pharma is a clinical-stage ophthalmic drug company focused on developing treatments for various eye diseases. Its research and development efforts target conditions including pterygium, pinguecula, meibomian gland dysfunction (MGD), and complications related to glaucoma filtration surgery. The company utilizes a potent multi-kinase inhibitor formulated as a topical eye drop for anterior segment diseases and an Antibody-Drug Synergism Platform for posterior segment diseases. Founded in September 2015, Cloudbreak Pharma is based in Irvine, California, with an additional office in Hong Kong.
The company is continuing to develop its pipeline of product candidates, which are at various stages of pre-clinical and clinical study. A key part of its future work involves creating the first therapeutic treatment for pterygia, which would introduce a new ophthalmic category. Its pipeline includes specific candidates like CBT-001, CBT-004, and CBT-009 for a variety of ocular conditions. The provided source material does not contain any specific recent company announcements.
- Grand Pharmaceutical
- V-Capital
- BOC International
- Lumiere Fund
- Hy Capital
- EFung Capital
- CDH Investments
- CCB International
- Dyee Capital
- Industrial Securities Capital
- CDF-Capital
- Yuejun Investment
- Yingke Capital
- ShenZhen GTJA Investment Group
- Co-Founder, Jinsong Ni
- Co-Founder, Van Dinh
- Co-Founder, Rong Yang
- Co-Founder, Bing Leng
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Cloudbreak Pharmaceutical worth joining?
Deciding whether to join any startup requires a careful evaluation of its equity compensation and growth potential. Platforms like Prospect can help you analyze a company’s prospects by using market data to project the future value of its equity.
What should I do with my Cloudbreak Pharmaceutical stock?
Managing private stock involves complex decisions around when to exercise options and how to plan for taxes to maximize your earnings. Financial tools from Prospect can build a personalized strategy to help you navigate these choices and make the most of your equity.
Can you sell Cloudbreak Pharmaceutical stock?
Since Cloudbreak Pharmaceutical is a private company, its stock is not publicly traded and can be difficult to sell. Opportunities to sell shares can arise during specific liquidity events like tender offers, which platforms like Prospect help you navigate.
How can I find the value of my Cloudbreak Pharmaceutical stock?
The current value of private stock is based on its fair market value (FMV), often from a 409A valuation. For future projections, platforms like Prospect use proprietary models and market data to help you understand the potential worth of your equity.
What is Cloudbreak Pharmaceutical's equity worth?
The precise worth of a private company’s equity is complex, depending on its latest valuation, market conditions, and growth prospects. To get a clearer picture, you can use a platform like Prospect, which provides data-driven projections on the potential value of your holdings.
What is Cloudbreak Pharmaceutical's stock ticker symbol?
As a privately held company, Cloudbreak Pharmaceutical does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they become publicly traded on a stock exchange.
Can I buy or sell Cloudbreak Pharmaceutical stock?
Buying stock is generally limited to employees exercising options or accredited investors, while selling is restricted to specific liquidity events like tender offers. Platforms such as Prospect offer tools to help employees manage both exercising their options and selling shares optimally.
What is the criteria to buy or invest in Cloudbreak Pharmaceutical stock?
Investing in a private company like Cloudbreak Pharmaceutical is generally not open to the public. Opportunities are typically reserved for employees receiving equity compensation or for accredited investors participating in private fundraising rounds.
